|
Shelf-life Extension of Azacitidine: Waste and Cost Reduction in the Treatment of Myelodysplastic Syndromes
|
May 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Short telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy.
|
Jun 2013
|
Transl Res
|
aplastic anemia
|
|
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
|
Oct 2015
|
Ann Oncol
|
myelodysplastic syndromes (MDS)
|
|
Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?
|
Oct 2013
|
Expert Rev Hematol
|
myelodysplastic syndromes (MDS)
|
|
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.
|
Mar 2019
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Silver lining: reduced relapse with chronic GVHD after transplant for MDS
|
Oct 2020
|
Clinical Cancer Research: an official Journal of the American Association of Cancer Research
|
graft versus host disease (GVHD), myelodysplastic syndromes (MDS)
|
|
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
|
Oct 2019
|
Blood Advances
|
aplastic anemia
|
|
Small-molecule Factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
|
Nov 2016
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes
|
May 2018
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
|
SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
|
Oct 2017
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
